Latest Eisai Stories

Research on a drug commonly prescribed to Alzheimer's disease patients is helping neuroscientists at the University of California, Berkeley, better understand perceptual learning in healthy adults.In a new study, to be published online Thursday, Sept. 16, in the journal Current Biology, researchers from UC Berkeley's Helen Wills Neuroscience Institute and School of Optometry found that study participants showed significantly greater benefits from practice on a task that involved...

ROCKAWAY, N.J., Aug. 5 /PRNewswire/ -- TekVault Corporation (www.tekvault.com), a Rockaway, NJ regulatory compliance consultancy and service provider, is announcing the extension of its existing infrastructure managed care service (IMSC) solution offering to Eisai, Inc. of Woodcliff Lake, NJ. Eisai, Inc. is a $3.9 billion U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., a research-based human health care company that discovers, develops and markets products throughout the...

SAN DIEGO, July 1, 2010 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Eisai Inc. will market lorcaserin for obesity and weight management in the United States following U.S. Food and Drug Administration (FDA) approval under the terms of a marketing and supply agreement between Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals, Inc., and Eisai. Lorcaserin, which Arena discovered and has developed for weight management,...

WOODCLIFF LAKE, N.J., March 25 /PRNewswire/ -- Eisai Inc. announced today that the Phase III ACCESS (A Controlled Comparison of Eritoran and Placebo in Patients with Severe Sepsis) trial of the investigational compound eritoran (E5564) will continue enrolling to the preset goal of 2,000 patients. As part of a planned interim analysis, an independent Data Monitoring Committee (DMC) has evaluated efficacy and safety data on the first 1,500 subjects to complete the 28-day follow-up in the...

WOODCLIFF LAKE, N.J., March 12 /PRNewswire/ -- Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces that it has entered into a licensing agreement with the Johns Hopkins University's Brain Science Institute (Headquarters: Baltimore, Maryland, Director: John Griffin, M.D., "BSI") related to Eisai's GCPII (glutamate carboxypeptidase II) technology. Under the terms of the agreement, Eisai has granted BSI non-exclusive U.S. rights to...

WALTHAM, Mass., Feb. 17, /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of moderate to severe Alzheimer's disease, a combination therapy that delays nursing home admission at 19 months would earn 43 percent patient share, according to surveyed U.S. neurologists. In comparison, in Europe, such an agent would earn a slightly lower patient share of 30 percent, according to...

WALTHAM, Mass., Jan. 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Pfizer/Medivation's Dimebon shows efficacy in two ongoing clinical trials in moderate to severe Alzheimer's disease that is equivalent to the impressive clinical trial data it has already shown to date in mild to moderate patients, these positive data would promote the use of Dimebon throughout the course of the disease....

WOODCLIFF LAKE, N.J., Jan. 6 /PRNewswire/ -- Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces the successful completion of its acquisition of the biopharmaceutical company, AkaRx, Inc. (Headquarters: Bridgewater, New Jersey, CEO: Robert E. Desjardins), for approximately $255 million. As a result of this acquisition, AkaRx is now a wholly-owned subsidiary of Eisai Inc. and Eisai has the exclusive worldwide rights to develop,...

WOODCLIFF LAKE, N.J., Nov. 11 /PRNewswire/ -- Eisai Inc. today announced that it has donated more than 80 pieces of artwork, created by its employees, to hospitals across the United States. The multi-panel murals were created by more than 1,200 of Eisai's field employees at a "PaintFest" team building event this summer. The event was conducted with the assistance of the Foundation for Hospital Art, which helps companies and organizations create artwork for donation to hospitals. The...

VIENNA, July 15 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the successful completion of a phase Ib/IIa trial in Alzheimer's disease patients with its nicotinic alpha-7 agonist EVP-6124. Subjects receiving EVP-6124 experienced improvement in cognition and EVP-6124 showed good tolerability and safety. The announcement came at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD) in Vienna, Austria where EnVivo presented its findings. EVP-6124 is...